- Home
- SCLXW vs ADAMG Comparison
SCLXW vs ADAMG Comparison
Compare SCLXW & ADAMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCLXW | ADAMG |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SCLXW | ADAMG |
|---|---|---|
| Price | $0.17 | $25.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.5K | ★ 13.4K |
| Earning Date | 03-07-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $55,152,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.02 | N/A |
| 52 Week Low | $0.04 | $24.02 |
| 52 Week High | $0.64 | $25.47 |
Technical Indicators
Market Signals| Indicator | SCLXW | ADAMG |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 57.16 |
| Support Level | $0.11 | $25.15 |
| Resistance Level | $0.18 | $25.23 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 51.11 | 42.08 |
Price Performance
Historical ComparisonAbout SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.